How Often Does the Fecal Test for Occult Blood Turn Positive After Using Blood Thinners?
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Fecal Immunochemical Test (FIT).
- Who it may be relevant to
- Registry conditions: Gastrointestinal Bleeding, Antiplatelet Agents, Oral Anticoagulant Therapy. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Jordan
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Exploring the Prevalence and Potential Benefits of Fecal Immunochemical Test Before Ana After Use of Antiplatelet and Anticoagulant Agents
Overview
Blood thinner medications used for cardiovascular disease can cause gastrointestinal bleeding. Early detection of invisible bleeding by performing occult fecal blood test (called fecal immunochemical test, or FIT) can uncover serious disease in the stomach and intestine and enable the treating physician to refer the patient for further evaluation.
Detailed description
Oral anticoagulant and antiplatelet agents (AC/AP agents) are the cornerstone of treatment in patients with cardiovascular disease (CVD), including those with coronary artery disease, atrial fibrillation and deep vein thrombosis/pulmonary embolism. However, these agents are associated with risk of gastrointestinal (GI) bleeding. The bleeding can unmask certain GI pathologies early such as peptic ulcer disease, polyps and cancer. The fecal immunochemical test (FIT) is the most commonly used test utilized in clinical practice to detect occult fecal blood. There is scarcity of studies in the Middle East that evaluate the frequency of positive FIT in patients with CVD prescribed AC/AP agents with an initially negative FIT and who do not have history of bleeding or GI disease.
The concept of the study relies on performing FIT before AC/AP initiation, and if negative, the test will be repeated after 3 months. If the repeat test turns positive , these patients will be referred for further GI evaluation.
Interventions
- Diagnostic test Fecal Immunochemical Test (FIT)
A stool sample will be tested by the FIT test to examine the presence or absence of fecal occult blood. Each participant will be tested twice; one before starting the oral antiplatelet or anticoagulant agents and the second 3 months after the use of the medication.
Primary outcome measures
- Positive Fecal Immunochemical Test [Time frame: From the time of enrollment to the end of the study at 3 months]
- Positive Fecal Immunochemical Test (FIT) [Time frame: From enrollment to the end of the study at 3 months]
Eligibility criteria
Inclusion criteria
- Adults aged 18 years or older.
- Have an indication to use oral antiplatelet or anticoagulant agent(s).
- Absence of past bleeding tendency of gastrointestinal disease.
- Agrees to have the test done (FIT).
- Agrees to sign the informed consent.
Exclusion criteria
- Presence of past bleeding tendency of gastrointestinal disease.
- Refusal to have the test done (FIT).
- Refusal to sign the informed consent.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Jordan · 1 center
- Istishari hospital — Amman
Identifiers
NCT: NCT07327853 · FIT/AP/AC#1.28.12.25